The present study examined the utility of daily naltrexone for decreasing alcohol drinking in hazardous drinkers. Forty-one participants participated in a 10-week trial and received 30 min of brief counseling on the first and second week of treatment, as well as a daily dose of 50 mg of naltrexone throughout the trial. Overall, naltrexone-treated participants did not show the same degree of improvement on drinking outcomes as placebo-treated participants. The placebo group drank fewer drinks per drinking day and achieved more abstinence days than the naltrexone group. Craving was also lower for the placebo group. The groups were not balanced on gender or family history of alcoholism and this may explain the lack of effect of naltrexone on the drinking outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.addbeh.2004.03.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alcohol consumption and incident heart failure in men and women.
Eur J Heart Fail
January 2025
Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Aims: Regular heavy alcohol consumption may lead to the development of alcohol-related cardiomyopathy and symptomatic heart failure (HF) later in life. However, the dose-response relationship between alcohol consumption and risk for incident HF, and whether these associations vary by sex and type of alcoholic beverage remains unclear.
Methods And Results: A total of 407 014 participants (52% women, age 56 years) from the UK Biobank who completed alcohol-related questionnaires and without a history of HF at baseline were included in the study.
Assessing Metabolic Ageing via DNA Methylation Surrogate Markers: A Multicohort Study in Britain, Ireland and the USA.
Aging Cell
January 2025
MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Metabolomics and epigenomics have been used to develop 'ageing clocks' that assess biological age and identify 'accelerated ageing'. While metabolites are subject to short-term variation, DNA methylation (DNAm) may capture longer-term metabolic changes. We aimed to develop a hybrid DNAm-metabolic clock using DNAm as metabolite surrogates ('DNAm-metabolites') for age prediction.
View Article and Find Full Text PDF[Association between possible sarcopenia and risk for frailty in middle-aged and elderly adults in China: a cohort study].
Zhonghua Liu Xing Bing Xue Za Zhi
January 2025
Institute of Population Research/Chinese Center for Population Health and Development, Peking University, Beijing100871, China.
To assess the association between possible sarcopenia and the risk for frailty in middle-aged and elderly adults in China. A prospective cohort study design was used in this study. Data were from the China Health and Retirement Longitudinal Study during 2011-2018 and the baseline data in 2011, the follow up was conducted in 2013, 2015 and 2018, respectively.
View Article and Find Full Text PDFControl mechanism of Escherichia coli invasion by micro-nano bubbles in drinking water distribution system.
Environ Res
January 2025
School of Environmental Science & Engineering, Tianjin University, Tianjin 300350, China.
Sudden biological contamination in Drinking Water Distribution System (DWDS) significantly threatens the safety of drinking water, with E. coli invasions being particularly hazardous to human health. Traditional disinfection methods (i.
View Article and Find Full Text PDFPBT/PMT assessment of active pharmaceutical ingredients.
Regul Toxicol Pharmacol
January 2025
AstraZeneca, Global Sustainability, The Netherlands.
The EU Commission proposal for a new EU pharmaceutical legislation considers PBT (persistence-bioaccumulation-toxicity) and PMT (persistence-mobility-toxicity) criteria for pharmaceuticals. Under current environmental risk assessment guidance, a PBT assessment is required regardless of the predicted environmental concentrations. However, consumption volumes of pharmaceuticals are contingent on marketing approval by EMA and are therefore predictable and their toxicological potency is established prior to any regulatory approval.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!